Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
11
Frequently Asked Questions
What is Market Cap of Rein Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Rein Therapeutics Inc. market cap is $31M.
What is the 52-week high for Rein Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Rein Therapeutics Inc. 52 week high is $4.40 as of September 07, 2025.
What is the 52-week low for Rein Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Rein Therapeutics Inc. 52 week low is $1.04 as of September 07, 2025.
What is Rein Therapeutics Inc. stock price today?
Rein Therapeutics Inc. stock price today is $1.33.
What was Rein Therapeutics Inc. stock price yesterday?
Rein Therapeutics Inc. stock price yesterday was $1.37.
What is the PE ratio of Rein Therapeutics Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Rein Therapeutics Inc.’s P/E ratio is -0.49.
What is the Price-to-Book ratio of Rein Therapeutics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Rein Therapeutics Inc. P/B ratio is 10.1900.
What is the 50-day moving average of Rein Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Rein Therapeutics Inc. 50-day moving average is $1.31.
How many employess does Rein Therapeutics Inc. has?
